Chesley Taft & Associates LLC bought a new position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 81,276 shares of the company’s stock, valued at approximately $15,412,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of AZN. Triumph Capital Management bought a new stake in Astrazeneca in the 3rd quarter valued at approximately $25,000. MV Capital Management Inc. bought a new position in shares of Astrazeneca during the 4th quarter worth approximately $26,000. Mascoma Wealth Management LLC acquired a new stake in shares of Astrazeneca in the first quarter valued at approximately $26,000. Roxbury Financial LLC acquired a new stake in shares of Astrazeneca in the second quarter valued at approximately $29,000. Finally, Eagle Bay Advisors LLC bought a new stake in shares of Astrazeneca in the fourth quarter worth $30,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
Astrazeneca Stock Performance
NYSE AZN opened at $161.28 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47. The firm’s fifty day moving average price is $176.34 and its two-hundred day moving average price is $187.11. Astrazeneca Plc has a 1 year low of $145.79 and a 1 year high of $212.71. The firm has a market capitalization of $250.12 billion, a P/E ratio of 24.11, a price-to-earnings-growth ratio of 1.39 and a beta of 0.26.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on AZN shares. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Finally, Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Astrazeneca presently has an average rating of “Moderate Buy” and a consensus price target of $211.00.
Read Our Latest Report on Astrazeneca
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
